ORIGINAL REPORT

INCREASED KNEE MUSCLE STRENGTH IS ASSOCIATED WITH DECREASED ACTIVITY LIMITATIONS IN ESTABLISHED KNEE OSTEOARTHRITIS: TWO-YEAR FOLLOW-UP STUDY IN THE AMSTERDAM OSTEOARTHRITIS COHORT

Diana C. Sanchez-Ramirez, PT, MPH, PhD[1,2], Marike van der Leeden, PhD[3,4], Martin van der Esch, PhD[3], Leo D. Roorda, MD, PT, PhD[3], Sabine Verschueren, PhD[5], Jaap van Dieën, PhD[2,6], Willem F. Lems, MD, PhD[7,8] and Joost Dekker, PhD[3,4,9]

From the [1]Injury Prevention Centre, University of Alberta, School of Public Health, Edmonton, Canada, [2]MOVE Research Institute Amsterdam, Faculty of Human Movement Sciences, VU University Amsterdam, [3]Amsterdam Rehabilitation Research Center, Reade, [4]VU University Medical Center, Department of Rehabilitation Medicine, Amsterdam, The Netherlands, [5]KU Leuven, Department of Rehabilitation Sciences, Belgium, [6]King Abdulaziz University, Jeddah, Saudi Arabia, [7]VU University Medical Center, Department of Rheumatology, [8]Jan van Breemen Research Institute, Reade and [9]VU University Medical Center, Department of Psychiatry, Amsterdam, The Netherlands

Objective: To examine the association between changes in knee muscle strength (extensor and flexor muscles separately, and mean values) and changes in activity limitations in patients with established knee osteoarthritis at 2 years.

Methods: Data from 186 patients with knee osteoarthritis, part of the Amsterdam Osteoarthritis cohort, were gathered at baseline and at 2-year follow-up. Strength of the knee extensor and flexor muscles were assessed using an isokinetic dynamometer. Activity limitations were assessed using the Western Ontario and McMaster University Osteoarthritis Index (WOMAC) – Physical Function subscale, the Get Up and Go test (GUG), and the 12-steps stairs test. Univariate and multivariate linear regression analyses were used to assess the association between changes in muscle strength and changes in activity limitations, adjusting for relevant confounders and baseline activity limitations.

Results: There was an overall 16% increase in mean knee muscle strength ($p<0.001$), 19% increase in knee extensor muscle strength ($p<0.001$), and 17% increase in knee flexor muscle strength ($p<0.001$) at 2 years. Increased mean knee muscle strength and knee flexor muscle strength were associated with better self-reported physical function (WOMAC) ($b=-5.7$, $p=0.03$ and $b=-6.2$, $p=0.05$), decreased time on the GUG ($b=-1.2$, $p=0.003$ and $b=-1.4$, $p=0.05$) and decreased time on the stairs test ($b=-4.4$, $p<0.001$ and $b=-6.6$, $p<0.001$). Increased extensor muscle strength was associated only with decreased time on the stairs test ($b=-2.7$, $p<0.001$).

Conclusion: Increased knee muscle strength, mainly in the knee flexors, was associated with decreased activity limitations in patients with knee osteoarthritis at 2 years. Thus, differences in muscle strength may partially explain the between-patients variability in activity limitations.

Key words: knee osteoarthritis; muscle strength; activity limitations.

J Rehabil Med 2015; 47: 647–654

Correspondence address: Diana C. Sanchez-Ramirez, University of Alberta, School of Public Health-Injury Prevention Centre, RTF 3-100A, T6G 2E1 Edmonton, Canada. E-mail: diana.sanchez@ualberta.ca

INTRODUCTION

Osteoarthritis (OA), the most common form of arthritis affecting the synovial joints, is considered a major cause of pain and activity limitations (1). Activity limitations are defined as difficulties in performing daily activities (2). Previous studies have shown a slow increase in activity limitations over time in patients with OA (3), while others have found no change, or even a decrease in activity limitations in this group of patients (4, 5). Nevertheless, there is high between-patients variability in the course of activity limitations in patients with OA, which requires further explanation (6, 7).

Muscle strength is considered a relevant determinant of activity limitations in patients with knee OA (5). The cross-sectional relationship between low muscle strength and activity limitations has been reported extensively (5, 8). Moreover, earlier studies have shown baseline muscle strength in patients with OA as a potential predictor for activity limitations in the long term (4, 6, 9, 10). The longitudinal association between a decrease in muscle strength and an increase in activity limitations has been studied in 2 observational studies, with conflicting results (4, 11), and in one clinical trial, which failed to control for relevant confounders (12). Overall, there is scarce evidence about the longitudinal association between muscle strength and activity limitations, in the absence of a well-defined intervention, in patients with established knee OA. Testing the longitudinal association between muscle strength and activity limitations in knee OA is a direct and necessary extension beyond cross-sectional research in this area.

Previous studies have focused mainly on the association of knee extensor muscle strength and activity limitations. There has been little research into the role of knee flexor muscle strength in activity limitations in patients with OA. However, in this group of patients an appropriate strength of the knee extensor and flexor muscles is important for stability of the knee and prevention of joint stress (13).

The aim of this study is to examine the association between changes in knee muscle strength (extensor and flexor muscles separately, and averaged) and changes in activity limitations in patients with established knee OA at 2 years. We hypothesized that, in patients with established OA, an increase in strength of the knee extensor and flexor muscles, as well as an increase in mean knee muscle strength, would be associated with a decrease in activity limitations in the long term.

PATIENTS AND METHODS

Patients

A total of 186 patients from the Amsterdam Osteoarthritis (AMS-OA) cohort (127 females, 59 males) with unilateral or bilateral diagnosis of knee OA according to the American College of Rheumatology (ACR) criteria (15) were included in this study. The AMS-OA is a cohort of patients with OA of the knee and/or hip (16, 17), who have been referred to an outpatient rehabilitation centre (Reade, Centre for Rehabilitation and Rheumatology, Amsterdam, The Netherlands) (14, 18). In the present study, the group of patients was defined as established knee OA due to the combination of confirmed diagnosis of knee OA according to ACR criteria and the presence of OA-related problems that led patients to seek specialized care. Patients were assessed by rheumatologists, radiologists and rehabilitation physicians. Exclusion criteria were rheumatoid arthritis or any other form of inflammatory arthritis (i.e. crystal arthropathy, septic arthritis, spondyloarthropathy), and total knee replacement during the follow-up period. Two years after the baseline assessment patients were invited to the follow-up assessment (Fig. 1) . Demographic, radiographic, clinical, psychosocial and biomechanical factors related to OA were assessed at baseline and at 2-year follow-up. The assessment of muscle strength and physical performance was completed by the same 2 trained movement scientists following an established and approved protocol. At follow-up, the data collectors did not have information on baseline assessment. Only patients who completed the assessment at both time-points were included in the study. All patients provided written inform consent according to the Declaration of Helsinki. The study was approved by the Reade Institutional Review Board.

Measures

Muscle strength. Knee muscle strength was assessed concentrically using an isokinetic dynamometer (EnKnee, Enraf-Nonius, Rotterdam, Netherlands) at baseline and at 2-year follow-up (18). Patients carried out an initial practice attempt to familiarize them with the required movements. The patients performed 3 maximal test repetitions to measure the isokinetic strength of the knee extensor muscles (mainly quadriceps) and knee flexor muscles (mainly hamstrings) for each knee, at 60°/s. The mean values of knee muscle strength (knee extensor and flexor combined, as well as mean knee extensor and mean flexor muscle strength (separate) per leg were calculated (Nm) and divided by the patient's weight (kg) (19). This measure (in Nm/kg) has shown an excellent intra-rater reliability (intraclass correlation coefficient (ICC) 0.93) in patients with knee OA (20). Muscle strength parameters were averaged over the 2 legs, due to the fact that 132 (71%) patients included in the study had OA in both knees and muscle strength in the 2 legs was highly correlated in our group of patients ($r = 0.82$, $p = 0.01$). In addition, optimal muscle strength in both legs is required for an appropriate performance of ambulatory activities of daily living.

Fig. 1. Patients course during the study. OA: osteoarthritis; ACR: American College of Rheumatology.

Activity limitations. Activity limitations were assessed using the Western Ontario and McMaster Universities Osteoarthritis physical function index subscale (WOMAC-PF), a self-reported questionnaire, and 2 physical performance tests (the Get Up and Go test (GUG) and the stairs test).

The WOMAC questionnaire was used to evaluate self-reported activity limitations, stiffness and pain in patients with OA (21). It has 5 items related to pain and 2 related to stiffness. The physical function (PF) section comprises 17 items, each scored 0–4, giving a possible total score of 0–68. Higher scores represent more activity limitations. A validated Dutch version of WOMAC (22) was used in this study.

The GUG test (23, 24) was performed with patients sitting on a high standard chair (seat height 49 cm). Patients were instructed to stand up without the help of the arms on the command "go", and walk 15 m along an unobstructed corridor as quickly as possible, without running. The chronometer was stopped when they reached a mark on the floor. All patients were wearing walking shoes. Patients who normally used walking devices were allowed to use them during the test. A longer time (s) taken to perform the test was considered a greater activity limitation.

In the stairs test (18), patients were instructed to climb 12 stairs (16 cm high), 1 stair at a time, as fast as possible, without running. Patients were encouraged not to use the handrail, but were not prohibited from doing so for safety. Once they reached the top, the chronometer was stopped while they turned around. Subsequently and following the same instructions, after a signal, the chronometer started again while the subjected descended the stairs. Both times (in s) were recorded independently and then added to calculate the time for the whole task. All patients were wearing comfortable walking shoes. A longer time performing the test was considered a higher activity limitation.

Potential confounders. Demographic data (i.e. age and gender) were recorded. Information related to comorbidities was collected with the Cumulative Illness Rating Scale (CIRS) (25). This instrument allows information to be gathered related to 13 body systems, scoring from 0 (none) to 4 (extremely severe) according to the severity of the condition. The number of diseases on which the patients scored a severity of 2 or higher was calculated and incorporated in the analyses. Body mass

index (BMI) was calculated as body mass in kg divided by height in m^2 (kg/m^2). C-reactive protein (CRP) (mg/l) levels were measured in serum from patients' blood samples and processed immunoturbidimetrically using CRPLX test kits (26–28) and the Roche Cobas-6000 analyser. Non-steroidal anti-inflammatory drug (NSAID) use was dichotomized (yes/no). Pain level was assessed using the WOMAC pain subscale (21). In addition, at 2-year follow-up the patients were asked if they had received physiotherapy at any institution or if they took part in a study involving physical therapy intervention during the past 2 years.

Statistical analysis

Descriptive statistics were used to characterize the study population at baseline and at 2-year follow-up. Percentages were used for categorical variables, medians (interquartile ranges (IQRs)) and means (standard deviations (SDs)) for continuous variables. McNemar tests and paired *t*-tests were used to analyse the differences in the distribution of the variables at baseline and at 2-year follow-up.

The baseline to 2-year follow-up change score was calculated for knee muscle strength (extensor and flexor muscles separately, and averaged) and activity limitations (WOMAC-PF, GUG and stairs test). The association between change in muscle strength (Nm/kg) and change in activity limitations was analysed using linear regression (analysis of covariance) (29). First, regression analyses were used to explore the association between change in muscle strength and change in activity limitations at 2-year follow-up, adjusting for baseline activity limitations (crude models) (29). Secondly, relevant confounding was defined as 10% change in the crude regression coefficient of the central determinant, after adjustment for an additional variable (30). The confounding effect of other variables possibly affecting the association between muscle strength and activity limitations (i.e. age, gender, change in comorbidities, change in NSAID use, change in BMI, change in CRP levels, change in WOMAC pain and physical therapy treatment) was evaluated based on a 10% difference between crude and adjusted regression coefficient. Thirdly, fully adjusted multivariable regression models including all relevant confounding variables were analysed.

Statistical significance was accepted at *p*-values < 0.05. All analyses were performed using SPSS software, version 18.0 (SPSS, Chicago, IL, USA).

RESULTS

Patients

A total of 268 patients with knee OA who completed the baseline assessment were invited to participate in the follow-up evaluation. Eight percent (*n* = 21) of the patients were excluded from the study due to total knee replacement. From the eligible patients who met the inclusion criteria at follow-up (*n* = 247), 25% (*n* = 61) declined the invitation for various reasons. Fig. 1 shows the patient flow during the study. There were no significant differences in baseline characteristics between the groups of patients who were and were not part of the 2-year follow-up assessment (Table I).

Descriptives

Demographic and clinical characteristics of the patients who participated at baseline and at 2-year follow-up (*n* = 186) are shown in Table II. Sixty-eight percent of the study group (*n* = 127) were women. Mean age at baseline was 61 years (SD 7.3). In the study group, there was an overall 16% increase in mean knee muscle strength mean (0.08 Nm/kg (SD 0.2); *p* < 0.001), 19% increase in knee extensor muscle strength (0.11 Nm/kg (SD 0.3); *p* < 0.001) and 17% increase in knee flexor muscle strength (0.06 Nm/kg (SD 0.2); *p* < 0.001) at 2 years. At the follow-up assessment, the time for completing the stairs test decreased in the study group

Table I. *Patients' baseline characteristics (*n = 247*)*

	Follow-up assessment completed	
	Yes (*n* = 186)	No (*n* = 61)
Age, years, mean (SD)	61 (7.3)	62 (8.6)
Radiographic OA K/L score ≥2, *n* (%)	131 (71)	44 (73)
BMI, kg/m², mean (SD)	29.3 (5.6)	28.8 (4.6)
CRP, mg/l, mean (SD)	3.4 (5.4)	2.5 (2.2)
Comorbidities count (CIRS ≥2), mean (SD)	0.8 (0.9)	0.6 (0.9)
NSAIDs (yes), *n* (%)	33 (18)	7 (12)
Knee muscle strength, Nm/kg, mean (SD)ᵃ	0.91 (0.4)	0.96 (0.4)
Knee extensor muscle strength, Nm/kg, mean (SD)	1.08 (0.4	1.15 (0.5)
Knee flexor muscle strength, Nm/kg, mean (SD)	0.73 (0.3)	0.78 (0.3)
WOMAC pain score (0–20), mean (SD)	7.9 (3.8)	7.9 (3.0)
WOMAC stiffness score (0–8), mean (SD)	3.7 (1.7)	4.1 (1.5)
WOMAC physical function score (0–68), mean (SD)	28.6 (13.4)	29.8 (11.4)
GUG, s, mean (SD)	11.1 (3.8)	10.8 (2.3)
Stairs test, s, mean (SD)	9.1 (3.5)	9.4 (5.9)

ᵃMean knee extensor and flexor muscle strength. Baseline characteristics were not significantly different between subgroups.
OA: osteoarthritis; K/L: Kellgren/Lawrence; SD: standard deviation; CIRS: Cumulative Illness Rating Scale; NSAIDs: non-steroidal anti-inflammatory drugs; WOMAC: Webster Ontario and McMaster Osteoarthritis index; GUG: Get Up and Go test.

(*p* = 0.039) and there was a borderline significant decrease in WOMAC-PF score (*p* = 0.053). However, there was no statistically significant change in mean time for completing the GUG test (*p* = 0.871) at 2 years.

Associations between changes in muscle strength and changes in activity limitations at 2 years

Tables III–V show the crude associations between change in knee muscle strength and change in activity limitations at 2 years. Increases in mean knee muscle strength and knee flexor muscle strength were significantly associated with a decrease in WOMAC-PF score, and a decrease in time (s) performing the GUG and the stairs test. After the addition of one possible confounder at the time to the crude models, comorbidities change, NSAIDs change and WOMAC pain change were identified as relevant confounders (i.e. more than 10% change in the crude model regression coefficient for the change in muscle strength). In the multivariable model, adjusted for all relevant confounders, increases in mean knee muscle strength and knee flexor muscle strength were still strongly associated with a decrease in WOMAC-PF score, and a decrease in time performing the GUG and the stairs test. In the crude models, an increase in knee extensor muscle strength was significantly associated with a decrease in WOMAC-PF score and a decrease in time performing the stairs test. However, in the fully adjusted models, increase in knee extensor muscle strength was only associated with a decrease in time performing the stairs test.

Possible effect of physical therapy

Additional analysis revealed that the association between increase in muscle strength and decrease in activity limitations

Table II. *Characteristics of the study population (*n = *186)*

	Baseline		Two-year follow-up		
	n		n		p
Age, years, mean (SD)	186	61 (7.3)	–	–	–
Female, *n* (%)	186	127 (68)	–	–	–
Radiographic OA, K/L score ≥2, *n* (%)	184	130 (70)	186	123 (66)	0.13
K/L score 2		58 (31)		55 (29)	
K/L score 3		52 (28)		31 (17)	
K/L score 4		20 (11)		37 (20)	
BMI, kg/m^2, mean (SD)	185	29.3 (5.5)	186	29.3 (5.4)	0.26
Comorbidities count (CIRS ≥2), mean (SD)	184	0.8 (1.0)	175	1.1 (1.0)	0.00
NSAIDs (yes), *n* (%)	185	30 (16)	186	38 (20)	0.23
CRP, mg/l, mean (SD)	183	3.4 (5.4)	184	2.9 (3.1)	0.21
Knee muscle strength, Nm/kg, mean (SD)[a]	177	0.92 (0.4)	183	0.98 (0.4)	0.00
Knee extensor muscle strength, Nm/kg, mean (SD)	179	1.1 (0.5)	185	1.2 (0.5)	0.00
Knee flexor muscle strength, Nm/kg, mean (SD)	181	0.7 (0.3)	184	0.8 (0.3)	0.00
WOMAC pain score (0–20), mean (SD)	183	7.9 (3.8)	185	7.0 (4.3)	0.01
WOMAC stiffness score (0–8), mean (SD)	179	3.7 (1.7)	186	3.5 (2.0)	0.02
WOMAC physical function score (0–68), mean (SD)	183	28.6 (13.4)	186	27.0 (15.3)	0.05
GUG, s, mean (SD)	185	11.0 (3.6)	185	10.9 (5.0)	0.87
Stairs test, s, mean (SD)	185	15.1 (8.8)	181	13.7 (7.3)	0.04
PT treatment during the past 2 years (yes), *n* (%)	–	No information	186	149 (80)	–

[a]Mean knee extensor and flexor muscle strength.

OA: osteoarthritis; K/L: Kellgren/Lawrence, CRP: C-reactive protein, PT: physiotherapy; SD: standard deviation; CIRS: Cumulative Illness Rating Scale; NSAIDs: non-steroidal anti-inflammatory drugs; WOMAC: Webster Ontario and McMaster Osteoarthritis index; GUG: Get Up and Go test; BMI: body mass index.

Table III. *Association between knee muscle strength change and changes in activity limitations over 2 years*

	WOMAC-PF score (0–68)			GUG test (s)			Stairs test (s)		
	b	95% CI	*p*-value	b	95% CI	*p*-value	b	95% CI	*p*-value
1 Crude Model									
KMS change	–9.5	–16.7, –2.3	0.01	–1.8	–3.0, –0.5	0.01	–4.4	–6.5, –2.3	<0.001
2 Adjusted Models									
KMS change									
+ gender	–9.4	–16.6, –2.2	0.01	–1.7	–2.9, –0.5	0.01	–4.4	–6.5, –2.3	<0.001
KMS change									
+ age	–9.2	–16.3, –2.2	0.01	–1.8	–3.0, –0.6	0.004	–4.4	–6.5, –2.3	<0.001
KMS change									
+ BMI change	–9.1	–16.3, –1.9	0.01	–1.8	–3.0, –0.5	0.01	–4.4	–6.5, –2.3	<0.001
KMS change									
+ CRP change	–9.3	–16.5, –2.0	0.01	–1.7	–3.0, –0.5	0.01	–4.3	–6.5, –2.2	<0.001
KMS change									
+ comorbidities change	–9.4	–17.0, –1.9	0.01	–1.4*	–2.5, –0.3	0.01	–4.2	–6.5, –2.0	<0.001
KMS change									
+ NSAIDs change	–9.1	–16.3, –1.9	0.01	–1.6*	–2.8, –0.4	0.01	–4.4	–6.5, –2.3	<0.001
KMS change									
+ WOMAC pain change	–5.7*	–10.9, –0.5	0.03	–1.5*	–2.5, –0.4	0.01	–4.2	–6.2, –2.2	<0.001
KMS change									
+ PT treatment	–9.3	–16.7, –2.0	0.01	–1.7	–3.0, –0.5	0.01	–4.3	–6.4, –2.2	<0.001
3 Fully Adjusted Model									
KMS change	–5.7[B1]	–10.9, –0.5	0.03	–1.2[B2]	–2.3, –0.1	0.03	–4.4[B3]	–6.5, –2.3	<0.001

Linear regression analysis using change in knee muscle strength (KMS) (mean extensor and flexor) as independent factor. Changes in WOMAC-PF (Webster Ontario and McMaster Osteoarthritis index – Physical Function), Get Up and Go test (GUG), time walking up and down a lap of 12 stairs as dependent variables.

b: regression coefficient; CI: confidence interval; CRP: C-reactive protein; NSAIDs: non-steroidal anti-inflammatory drugs; PT: physiotherapy. All models were adjusted for baseline activity limitations (analysis of covariance).

*Factor affects the coefficient 10% or more. Reduce patient numbers in the multivariate linear regression analyses due to random data missing in the outcome measure or selected variables.

1: Crude Model; 2: Adjusted Model for relevant confounders; 3: Full Adjusted Model for factors affecting the crude coefficient 10% or more: [B1]Adjusted for WOMAC pain change and baseline WOMAC-PF; [B2]Adjusted for comorbidities change, NSAIDS change, WOMAC pain change and baseline GUG test; [B3]Adjusted for baseline stairs test.

Table IV. *Association between knee extensor muscle strength change and changes in activity limitations over 2 years*

	WOMAC-PF score (0–68)			GUG test (s)			Stairs test (s)		
	b	95% CI	*p*-value	b	95% CI	*p*-value	b	95% CI	*p*-value
1 Crude Model									
Knee extensor muscle strength (EMS) change	–5.9	–11.2, –0.7	0.03	–0.9	–2.0, 0.1	0.08	–2.7	–4.2, –1.1	0.001
2 Adjusted Models									
EMS change + gender	–6.0	–11.2, –0.7	0.03	–1.0*	–2.0, 0.1	0.07	–2.7	–4.2, –1.1	0.001
EMS change + age	–5.9	–11.1, –0.7	0.03	–0.9	–2.0, 0.1	0.08	–2.7	–4.2, –1.1	0.001
EMS change + BMI change	–5.7	–11.0, –0.4	0.03	–0.9	–1.9, 0.2	0.10	–2.6	–4.2, –1.1	0.001
EMS change + CRP change	–5.1*	–10.5, 0.3	0.06	–0.8*	–1.9, 0.3	0.15	–2.7	–4.3, –1.1	0.001
EMS change + comorbidities change	–5.6	–11.0, –0.2	0.04	–0.9	–1.9, 0.1	0.09	–2.6	–4.2, –1.0	0.002
EMS change + NSAIDs change	–5.7	–11.0, –0.4	0.03	–0.9	–1.9, 0.2	0.10	–2.7	–4.2, –1.1	0.001
EMS change + WOMAC pain change	–3.8*	–7.5, 0.01	0.05	–0.9	–2.0, 0.1	0.07	–2.6	–4.1, –1.1	0.001
EMS change + PT treatment	–5.8	–11.1, –0.4	0.04	–0.9	–2.0, 0.1	0.09	–2.6	–4.1, –1.0	0.001
3 Fully Adjusted Model									
EMS change	–2.8[B1]	–6.6, 1.0	0.15	–0.8[B2]	–1.9, 0.2	0.12	–2.7[B3]	–4.2, –1.1	0.001

Linear regression analysis using change in knee extensor muscle strength as independent factor. Changes in WOMAC-PF (Webster Ontario and McMaster Osteoarthritis index-Physical Function), Get Up and Go test (GUG), time walking up and down a lap of 12 stairs as dependent variables. b: regression coefficient; CI: confidence interval; CRP: C-reactive protein; NSAIDs: non-steroidal anti-inflammatory drugs; PT: physiotherapy. All models were adjusted for baseline activity limitations (analysis of covariance).
*Factor affects the coefficient 10% or more. Reduce patient numbers in the multivariate linear regression analyses due to random data missing in the outcome measure or selected variables.
1: Crude Model; 2: Adjusted Model for relevant confounders; 3: Fully Adjusted Model for factors affecting the crude coefficient 10% or more: [B1]Adjusted for CRP change, WOMAC pain change and baseline WOMAC-PF; [B2]Adjusted for gender, CRP change and baseline GUG test; [B3]Adjusted for baseline stairs test.

occurred among those subjects who had received physical therapy interventions, and not among subjects who did not receive physical therapy (Table VI).

DISCUSSION

This study showed an association between increase in muscle strength and a decrease in activity limitations in patients with established knee OA at 2 years. This association suggests that muscle strength may partially explain the between-patients variability in the course of activity limitations. To the best of our knowledge, and based on a thorough review of the literature, this is the first observational study to describe the longitudinal association between knee muscle strength (extensor and flexor muscles separately, and averaged) and activity limitations in patients with established knee OA.

This study represents an extension of evidence from previous cross-sectional, prediction models and intervention studies (4–6, 9, 10, 12), which have previously reported an association between knee muscle strength and activity limitations. The additional value of the current observational study is the longitudinal association between knee extensor and flexor muscles strength separately, as well as mean knee muscle strength, with activity limitations in patients with established

knee OA. A longitudinal association was found for increases in mean knee muscle strength and in knee flexor muscles strength, and a decrease in all the measures of activity limitations assessed. However, increase in knee extensor muscle strength was associated only with a decrease in the stairs tests, which is a highly demanding performance activity. Moreover, the overall association found in the present study was confirmed in another longitudinal study carried out by our research group in patients with early OA (31).

Eighty percent of the study population reported having received some type of physical therapy intervention during the 2-year follow-up. This could explain the overall increase in muscle strength and decrease in activity limitations in the study group at 2 years. This interpretation is in line with the observation that the association between increase in muscle strength and decrease in activity limitations was limited to those subjects who had received physical therapy interventions. Previous evidence has suggested that muscle weakness may precede activity limitations in patients with knee OA (7, 10); with improvement seen after muscle strengthening interventions (32–36). The linear relationship between increased muscle strength and decreased activity limitations might be explained by the important role of muscle function in the knee joint. The muscles around the knee control the stop/start of

Table V. *Association between knee flexor muscle strength change and changes in activity limitations over 2 years*

	WOMAC-PF score (0–68)			GUG test (s)			Stairs test (s)		
	b	95% CI	*p*-value	b	95% CI	*p*-value	b	95% CI	*p*-value
1 Crude Model									
Knee flexor muscle strength (FMS) change	−13.9	−22.3, −5.5	0.001	−1.9	−3.4, −0.4	0.01	−7.3	−10.3, −4.4	<0.001
2 Adjusted Models									
FMS change + gender	−13.8	−22.3, −5.4	0.001	−1.9	−3.4, −0.4	0.01	−7.4	−10.4, −4.5	<0.001
FMS change + age	−13.6	−21.9, −5.3	0.001	−1.9	−3.4, −0.4	0.01	−7.3	−10.3, −4.4	<0.001
FMS change + BMI change	−13.4	−21.9, −5.0	0.002	−1.9	−3.4, −0.4	0.01	−7.3	−10.3, −4.3	<0.001
FMS change + CRP change	−12.8	−21.2, −4.5	0.003	−1.7*	−3.2, 0.2	0.03	−7.1	−10.1, −4.2	<0.001
FMS change + comorbidities change	−14.7	−23.7, −5.8	0.001	−2.0	−3.4, −0.6	0.01	−7.5	−10.8, −4.3	<0.001
FMS change + NSAIDs change	−13.1	−21.3, −4.7	0.003	−1.6*	−3.0, −0.1	0.03	−7.3	−10.3, −4.3	<0.001
FMS change + WOMAC pain change	−6.2*	−12.3, −0.1	0.05	−1.8	−3.1, −0.5	0.01	−6.6*	−9.5, −3.7	<0.001
FMS change + PT treatment	−14.1	−22.8, −5.3	0.002	−1.9	−3.4, −0.3	0.02	−7.2	−10.3, −4.2	<0.001
3 Fully Adjusted Model									
FMS change	−6.2[B1]	−12.3, −0.1	0.05	−1.4[B2]	−2.9, 0.01	0.05	−6.6[B3]	−9.5, −3.7	<0.001

Linear regression analysis using change in knee flexor muscle strength as independent factor. Changes in WOMAC-PF (Webster Ontario and McMaster Osteoarthritis index-Physical Function), Get Up and Go test (GUG), time walking up and down a lap of 12 stairs as dependent variables. b: regression coefficient; CI: confidence interval; CRP: C-reactive protein; NSAIDs: non-steroidal anti-inflammatory drugs; PT: physiotherapy. All the models were adjusted for the baseline activity limitations (analysis of covariance).

*Factor affects the coefficient 10% or more. Reduce patient numbers in the multivariate linear regression analyses due to random data missing in the outcome measure or selected variables.

1: Crude Model; 2: Adjusted Model for relevant confounders; 3: Fully Adjusted Model for factors affecting the crude coefficient 10% or more: [B1]Adjusted for WOMAC pain change and baseline WOMAC-PF; [B2]Adjusted for CRP change, NSAIDS change and baseline GUG test; [B3]Adjusted for WOMAC pain change and baseline stairs test.

the joint motion, add stability and redistribute joint load. In addition, appropriate co-contraction of the knee extensor and flexor muscles allows the upright position to be maintained, compensating for gravity during standing or while performing activities (4). Besides the direct association between improvement in muscle strength and decrease in activity limitations, which can probably be explained by the participation of 80% of the study group in some kind of physical therapy, it is possible

that indirect pathways may also have influenced this relationship. For example, it is probable that an improvement in muscle strength might contribute to an increase in self-confidence, resulting in better performance of activities.

The strength of the association between change in muscle strength and change in activity limitations was moderate (stairs test r=−0.26, p=0.001 and GUG tests r=−0.23, p=0.005). However, given the small changes in strength and activity

Table VI. *Association between knee muscle strength change and changes in activity limitations over 2 years (*n = 186*)*

	WOMAC-PF score (0–68)			GUG test (s)			Stairs test (s)		
	b	95% CI	*p*-value	b	95% CI	*p*-value	b	95% CI	*p*-value
Subjects reporting PT treatment (*n*=149)									
Knee muscle strength (FMS) change	−10.3	−18.1, −2.4	0.011	−1.7	−3.2, −0.4	0.010	−4.4	−6.8, −2.1	<0.001
Knee extensor muscle strength (FMS) change	−6.9	−12.8, −1.1	0.020	−1.0	−2.2, 0.2	0.095	−2.9	−4.6, −1.2	0.001
Knee flexor muscle strength (FMS) change	−14.5	−23.8, −5.1	0.003	−2.0	−3.7, −0.3	0.021	−7.1	−10.5, −3.8	<0.001
Subjects not reporting PT treatment (*n*=37)									
Knee muscle strength (FMS) change	−3.9	−25.7, 17.7	0.714	−1.7	−4.7, 1.2	0.239	−2.9	−8.5, 2.8	0.308
Knee extensor muscle strength (FMS) change	−0.9	−14.7, 12.9	0.901	−0.8	−2.7, 1.0	0.396	−1.0	−4.5, 2.6	0.576
Knee flexor muscle strength (FMS) change	−10.7	−37.3, 15.8	0.417	−1.2	−5.1, 2.6	0.507	−3.8	−10.9, 3.2	0.278

Linear regression analysis using change in knee muscle strength (KMS) as independent factor. Changes in WOMAC-PF (Webster Ontario and McMaster Osteoarthritis index-Physical Function), Get Up and Go test (GUG), time walking up and down a lap of 12 stairs as dependent variables. b: regression coefficient; CI: confidence interval; CRP: C-reactive protein; NSAIDs: non-steroidal anti-inflammatory drugs; PT: physiotherapy. All models were adjusted for baseline activity limitations (analysis of covariance).

limitations, the observed association is of considerable interest. There was stronger association between change in mean knee muscle strength and change in performance-based tests (stairs test r = –0.26, *p* = 0.001 and GUG test r = –0.23, *p* = 0.005) than with changes in self-reported activity limitations (WOMAC-PF r = –0.16, *p* = 0.031). This may be due to the influence of additional psychosocial factors potentially involved in a self-reported measure such as WOMAC-PF. Increase in knee extensor muscle strength was associated with better performance on the stairs test at 2 years, while increase in knee flexor muscle strength was associated not only with better performance tests, but also with a decrease in self-reported activity limitations at 2-year follow-up. Knee flexor muscles are usually weaker than knee extensor muscles (37). This strength imbalance is partly due to the larger size of the main knee extensor muscles (quadriceps) compared with the main flexors muscles (hamstrings). Although more attention has commonly been given to the assessment of knee extensor muscles due to their leading role within activity limitations (38–40), the findings of the present study suggest a relevant involvement of knee flexor muscles in activity limitations over time in patients with OA, highlighting the importance of incorporating training of these muscles in intervention programmes.

Study limitations and strengths

Some limitations of this study must be taken into account. First, 25% of patients dropped out the study at follow-up. However, the relevant baseline characteristics were not statistically different between patients who completed and did not complete the follow-up assessment (Table I), which makes us believe that this loss of patients at follow-up did not impact the results of our study. It is possible that the patients who did not attend the follow-up assessment might have had a decline in their overall condition, including a decrease in muscle strength and an increase in activity limitations, which might have prevented them from visiting the assessment centre. On the other hand, the opposite may also have occurred: patients who experienced an improvement in their condition might no longer be interested in taking part in the study. The loss of patients may thus have caused either an under- or over-estimation of our results. Secondly, it was not possible to collect exact information about the quantity or kind of physical therapy treatment received by the patients. This was because the physical therapy reported did not necessarily take place at our rehabilitation centre. Therefore, only dichotomous information about receiving therapy or not (yes/no) was available.

A significant positive change in muscle strength was observed in the group of patients who received (*n* = 149) compared with the group who did not receive (*n* = 37) physical therapy during the follow-up period (data not shown). However, as the group who did not receive physical therapy was very small, no separate analyses were presented. Nevertheless, this potential confounder was considered in the study, and the crude coefficient was not affected after adjusting the model for physical therapy treatment. Key strengths of our study are the large number of patients with knee OA (*n*=186) studied and a longitudinal design.

Further research

From a clinical perspective, the results of this study support muscle strength training interventions in patients with knee OA. Previous intervention studies have found muscle strength training interventions to be effective to decrease activity limitations in patients with knee OA (32–36). However, the optimal type and amount of exercise to be implemented require further definition. In addition, these results highlight the importance of training both knee extensor and flexor muscles within the intervention programmes. Overall, in patients with OA, optimal delivery of muscle strength training might contribute to a decrease in activity limitations and to a subsequent decrease in participation restrictions. However, further longitudinal observational-studies are needed to test these hypotheses in a larger group of patients with established knee OA. We also suggest incorporating multiple assessment times over a longer follow-up period in order to determine the progression of the changes and the associations.

In conclusion, an increase in knee muscle strength, mainly in the knee flexor muscles, was associated with a decrease in activity limitation in patients with knee OA after 2 years. These results suggest that muscle strength may partially explain the between-patient variability in activity limitations over time.

REFERENCES

1. Pendleton A, Arden N, Dougados M, Doherty M, Bannwarth B, Bijlsma JW, et al. EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2000; 59: 936–944.
2. World Health Organization (WHO). International classification of functioning, disability and health: ICF. Geneva: WHO; 2001.
3. van Dijk GM, Dekker J, Veenhof C, Van den Ende CH. Course of functional status and pain in osteoarthritis of the hip or knee: a systematic review of the literature. Arthritis Rheum 2006; 55: 779–785.
4. Sharma L, Cahue S, Song J, Hayes K, Pai YC, Dunlop D. Physical functioning over three years in knee osteoarthritis: role of psychosocial, local mechanical, and neuromuscular factors. Arthritis Rheum 2003; 48: 3359–3370.
5. McAlindon TE, Cooper C, Kirwan JR, Dieppe PA. Determinants of disability in osteoarthritis of the knee. Ann Rheum Dis 1993; 52: 258–262.
6. Holla JF, Steultjens MP, Roorda LD, Heymans MW, Ten WS, Dekker J. Prognostic factors for the two-year course of activity limitations in early osteoarthritis of the hip and/or knee. Arthritis Care Res (Hoboken) 2010; 62: 1415–1425.
7. Pisters MF, Veenhof C, van Dijk GM, Heymans MW, Twisk JW, Dekker J. The course of limitations in activities over 5 years in patients with knee and hip osteoarthritis with moderate functional limitations: risk factors for future functional decline. Osteoarthritis Cartilage 2012; 20: 503–510.
8. O'Reilly SC, Jones A, Muir KR, Doherty M. Quadriceps weakness

in knee osteoarthritis: the effect on pain and disability. Ann Rheum Dis 1998; 57: 588–594.

9. Amin S, Baker K, Niu J, Clancy M, Goggins J, Guermazi A, et al. Quadriceps strength and the risk of cartilage loss and symptom progression in knee osteoarthritis. Arthritis Rheum 2009; 60: 189–198.

10. Miller ME, Rejeski WJ, Messier SP, Loeser RF. Modifiers of change in physical functioning in older adults with knee pain: the Observational Arthritis Study in Seniors (OASIS). Arthritis Rheum 2001; 45: 331–339.

11. van Dijk GM, Veenhof C, Spreeuwenberg P, Coene N, Burger BJ, van Schaardenburg D, et al. Prognosis of limitations in activities in osteoarthritis of the hip or knee: a 3-year cohort study. Arch Phys Med Rehabil 2010; 91: 58–66.

12. Maurer BT, Stern AG, Kinossian B, Cook KD, Schumacher HR, Jr. Osteoarthritis of the knee: isokinetic quadriceps exercise versus an educational intervention. Arch Phys Med Rehabil 1999; 80: 1293–1299.

13. Hayes KW, Falconer J. Differential muscle strength decline in osteoarthritis of the knee. A developing hypothesis. Arthritis Care Res 1992; 5: 24–28.

14. Altman RD. Criteria for classification of clinical osteoarthritis. J Rheumatol Suppl 1991; 27: 10–12.

15. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 1986; 29: 1039–1049.

16. Altman R, Alarcon G, Appelrouth D, Bloch D, Borenstein D, Brandt K, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum 1991; 34: 505–514.

17. Knoop J, van der Leeden M, van der Esch M, Thorstensson CA, Gerritsen M, Voorneman RE, et al. Association of lower muscle strength with self-reported knee instability in osteoarthritis of the knee: results from the Amsterdam Osteoarthritis Cohort. Arthritis Care Res (Hoboken) 2012; 64: 38–45.

18. Sanchez-Ramirez DC, van der Leeden M, Knol DL, van der Esch M, Roorda LD, Verschueren S, et al. Association of postural control with muscle strength, proprioception, self-reported knee instability and activity limitations in patients with knee osteoarthritis. J Rehabil Med 2013; 45: 192–197.

19. van der Esch M, Steultjens M, Harlaar J, Knol D, Lems W, Dekker J. Joint proprioception, muscle strength, and functional ability in patients with osteoarthritis of the knee. Arthritis Rheum 2007; 57: 787–793.

20. Kean CO, Birmingham TB, Garland SJ, Bryant DM, Giffin JR. Minimal detectable change in quadriceps strength and voluntary muscle activation in patients with knee osteoarthritis. Arch Phys Med Rehabil 2010; 91: 1447–1451.

21. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988; 15: 1833–1840.

22. Roorda LD, Jones CA, Waltz M, Lankhorst GJ, Bouter LM, van der Eijken JW, et al. Satisfactory cross cultural equivalence of the Dutch WOMAC in patients with hip osteoarthritis waiting for arthroplasty. Ann Rheum Dis 2004; 63: 36–42.

23. van der Esch M, Steultjens M, Harlaar J, Wolterbeek N, Knol D, Dekker J. Varus-valgus motion and functional ability in patients with knee osteoarthritis. Ann Rheum Dis 2008; 67: 471–477.

24. Hurley MV, Scott DL, Rees J, Newham DJ. Sensorimotor changes

and functional performance in patients with knee osteoarthritis. Ann Rheum Dis 1997; 56: 641–648.

25. Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. J Am Geriatr Soc 1968; 16: 622–626.

26. Price CP, Trull AK, Berry D, Gorman EG. Development and validation of a particle-enhanced turbidimetric immunoassay for C-reactive protein. J Immunol Methods 1987; 99: 205–211.

27. Sanchez-Ramirez DC, van der Leeden M, van der Esch M, Gerritsen M, Roorda LD, Verschueren S, et al. Association of serum C-reactive protein and erythrocyte sedimentation rate with muscle strength in patients with knee osteoarthritis. Rheumatology (Oxford) 2013; 52: 727–732.

28. Senju O, Takagi Y, Uzawa R, Iwasaki Y, Suzuki T, Gomi K, et al. A new immuno quantitative method by latex agglutination–application for the determination of serum C-reactive protein (CRP) and its clinical significance. J Clin Lab Immunol 1986; 19: 99–103.

29. Twisk Jos W. Applied longitudinal data analysis for epidemiology: a practical guide. Cambridge: Cambrige University Press; 2003, p. 167–178.

30. Kleinbaum DG, Kupper LL, Muller KE. Applied regression analysis and other multivariable methods. Boston: PWS-Kent Publishing Co.; 1988.

31. van der Esch M, Holla JF, van der Leeden M, Knol DL, Lems WF, Roorda LD, et al. Decrease of muscle strength is associated with increase of activity limitations in early knee osteoarthritis: 3-year results from the Cohort Hip and Cohort Knee study. Arch Phys Med Rehabil 2014; 95: 1962–1968.

32. Baker KR, Nelson ME, Felson DT, Layne JE, Sarno R, Roubenoff R. The efficacy of home based progressive strength training in older adults with knee osteoarthritis: a randomized controlled trial. J Rheumatol 2001; 28: 1655–1665.

33. Chaipinyo K, Karoonsupcharoen O. No difference between home-based strength training and home-based balance training on pain in patients with knee osteoarthritis: a randomised trial. Aust J Physiother 2009; 55: 25–30.

34. Ettinger WH, Jr, Burns R, Messier SP, Applegate W, Rejeski WJ, Morgan T, et al. A randomized trial comparing aerobic exercise and resistance exercise with a health education program in older adults with knee osteoarthritis. The Fitness Arthritis and Seniors Trial (FAST). JAMA 1997; 277: 25–31.

35. O'Reilly SC, Muir KR, Doherty M. Effectiveness of home exercise on pain and disability from osteoarthritis of the knee: a randomised controlled trial. Ann Rheum Dis 1999; 58: 15–19.

36. Rogind H, Bibow-Nielsen B, Jensen B, Moller HC, Frimodt-Moller H, Bliddal H. The effects of a physical training program on patients with osteoarthritis of the knees. Arch Phys Med Rehabil 1998; 79: 1421–1427.

37. Rosene JM, Fogarty TD, Mahaffey BL. Isokinetic hamstrings: quadriceps ratios in intercollegiate athletes. J Athl Train 2001; 36: 378–383.

38. Hurley MV, Scott DL. Improvements in quadriceps sensorimotor function and disability of patients with knee osteoarthritis following a clinically practicable exercise regime. Br J Rheumatol 1998; 37: 1181–1187.

39. Ling SM, Xue QL, Simonsick EM, Tian J, Bandeen-Roche K, Fried LP, et al. Transitions to mobility difficulty associated with lower extremity osteoarthritis in high functioning older women: longitudinal data from the Women's Health and Aging Study II. Arthritis Rheum 2006; 55: 256–263.

40. Slemenda C, Brandt KD, Heilman DK, Mazzuca S, Braunstein EM, Katz BP, et al. Quadriceps weakness and osteoarthritis of the knee. Ann Intern Med 1997; 127: 97–104.